Compare Ascendis Pharma A/S (ASND) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Illumina, Inc. — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.67B), while Illumina, Inc. trades at $193.06 (market cap $29.12B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, Ascendis Pharma A/S nearer its low. Which is the better fit depends on your goals.
| ASND | ILMN | |
|---|---|---|
Market Cap | $16.67B | $29.12B |
Sector | Health | Health |
52-Week High | $277.18 | $205.10 |
52-Week Low | $189.74 | $91.00 |
Enterprise Value | $17.04B | $30.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
